Kreatis in MBO from Cehtra
In silico testing specialist Kreatis has undergone a buy-out by the management team after 12 years as a subsidiary company of the Cehtra group in France. It will continue to be headed by Paul Thomas, president and founder of the firm in 2014.
According to Kreatis, this was done to give it total autonomy, allowing it to expand its partnerships, as well as access to new sources of funding in order to be able to carry out “a more ambitious research programme”. Thomas commented: “We are looking forward to putting all our energy into new and exciting projects in the area of alternative testing methods.”
RELATED ARTICLES
UK-based speciality chemicals company Elementis has announced that, by mutual agreement, CEO Paul Waterman will step down no later than the AGM in April 2025, remaining available as required for any transition or other support until the end of July. A successor is now being sought.
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
International Chemical Investors Group (ICIG), the owner of WeylChem and many other European chemical assets, has acquired the European Advanced Organics business of Valtris Specialty Chemicals.
SOCMA, the trade association of the US speciality chemical manufacturing industry, has published an open letter to the pending Trump administration, urging it to “prioritise policies that encourage advancement, streamline regulatory processes and incentivise domestic manufacturing”.
BASF has formed a partnership with Slovenian white biotech Acies Bio. Under this it will further develop the latter’s OneCarbonBio fermentation platform to derive methanol for the production of fatty alcohols for home and personal care ingredients, notably surfactants.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
